Pop icon Paula Abdul has taken on the role of brand ambassador for the world’s first consumer take-home skincare serum created with the purchaser’s own PRP (Platelet Rich Plasma).
Launched by Aesthetics Biomedical (ABM), the SoME serum will be sold in skincare clinics where a medical practitioner will draw blood from the client to “extract sufficient PRP to be combined with the SoME base serum to create a truly personalized topical skincare product”.
According to Aesthetics Biomedical CEO, MaryAnn Guerra, SoMe is a skin rejuvenating treatment designed to target fine lines, wrinkles, dryness, discoloration, and reduces puffiness and darkness around the eyes.
To buy the product, Guerra said consumers would have to go to a skincare clinic for a consultation with a medical practitioner who would then draw the required amount of PRP from them to create their personalised serum. When the “quick process” is completed, the consumer can then take home the “translucent, smooth textured serum” in a branded skincare refrigerator (sold with the initial purchase) and use it twice daily to rejuvenate their skin.
“Until now, there has never been an autologous skincare product with proven results. SoME™+ Platelet Rich Plasma (PRP) uses the body’s own regenerative properties to stimulate natural collagen and elastin for visibly renewed firmness and luminosity,” she said.
“The cosmetic serum was formulated and rigorously tested by Aesthetics Biomedical to ensure that when combined with an individual’s PRP, as recommended by a physician, the platelets are preserved for optimal effect upon use.
“Preservation of the platelet components is key as this discovery allows the product to remain efficacious over the course of three months, setting a new standard in the industry.”
Abdul said she was passionate about partnering with ABM as she had been looking for skincare that’s natural “and truly personalised to me”.
“I found it with SoME,” she said. “It keeps my skin looking radiant despite my busy lifestyle.”
For more news and updates, subscribe to our weekly newsletter.